Form 4 Filing for Avalo Therapeutics, Inc.

On April 1st and 2nd, 2026, Christopher Ryan Sullivan, Chief Financial Officer of Avalo Therapeutics, Inc., reported the sale of 15,759 shares of common stock. These transactions were executed under a Rule 10b5-1 trading plan adopted on November 12, 2025. The sales occurred in multiple tranches at prices ranging from $15.24 to $17.80 per share. Following these transactions, Mr. Sullivan’s reported ownership of common stock decreased, with post-transaction holdings detailed in the filing. The specific number of shares sold at each price point within the reported ranges will be provided upon request by the Issuer, SEC staff, or any security holder.